Our group is actively engaged in a range of cutting-edge biomedical imaging and theranostic projects. One of our major focuses is the development of antibody-conjugated fluorescent dyes for multispectral fluorescence imaging of dysplasia, particularly in the 4NQO-induced model. By targeting dysplastic tissue with high specificity using fluorescently labeled antibodies, we aim to enhance early detection and visualization of precancerous lesions. Additionally, we are advancing dual-modal image-guided treatment strategies through the use of antibody-coated nanobodies. These multifunctional platforms integrate both imaging and therapeutic functions, offering precise detection and intervention for head and neck squamous cell carcinoma (HNSCC) and related dysplasias.
We are also innovating in the field of NIR-II (near-infrared II) image-guided phototherapy, designing novel molecules that provide deeper tissue penetration and higher resolution imaging compared to conventional NIR-I agents. These molecules are engineered to serve both as imaging contrast agents and as phototherapeutic agents, enabling highly targeted treatment. Furthermore, our group is exploring nanotheranostic platforms based on ultrasound and MRI technologies to deliver real-time imaging coupled with responsive therapy. By combining multiple imaging modalities and treatment mechanisms, our goal is to create highly effective, personalized strategies for the diagnosis and treatment of cancer and precancerous conditions.